ASH 2022 | An ongoing Phase I/II dose-finding study of ZN-d5 for R/R AL amyloidosis
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, describes the design of the ZN-d5-003 Phase I trial evaluating ZN-d5, a novel BCL-2 inhibitor, in patients with relapsed/refractory (R/R) AL amyloidosis (NCT05199337). This ongoing trial is currently determining the optimal dose of ZN-d5 before proceeding to investigate the efficacy of the agent in AL amyloidosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
